Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ACTRN12626000586314) titled 'ALLG NHL44: A Phase 2, Multicenter, Single-Arm Study to Evaluate Polatuzumab vedotin-Rituximab with/without Radiotherapy as a Bridging Therapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Prior to CD19 CAR-T Cell Therapy' on May 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Australasian Leukaemia and Lymphoma Group
Condition:
Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Intervention:
Participants will receive bridging therapy ...